Boehringer boosts obesity and liver health unit with new hire

German pharma major Boehringer Ingelheim has appointed Vani Manja as senior vice president and global head of its newly formed obesity and liver health unit. The move signals Boehringer’s determination to capture share in two of the fastest-growing therapeutic areas worldwide.

Ms Manja, who has more than 20 years of healthcare experience, was most recently the company’s country managing director and head of human pharma in the UK and Ireland. She joined Boehringer in 2011 and has since held a series of international leadership positions spanning the USA, Germany, Japan, and India.

Rising stakes in obesity and liver disease